| CAS NO: | 1217629-70-3 |
| 包装: | 1mg |
| 市场价: | 4914元 |
| Cas No. | 1217629-70-3 |
| Canonical SMILES | O=C(C1=CC=CC(O)=C1C([2H])([2H])[2H])N[C@H]([C@H](O)CN2C[C@](CCCC3)([H])[C@]3([H])C[C@H]2C(NC(C)(C)C)=O)CSC4=CC=CC=C4 |
| 分子式 | C32H42D3N3O4S |
| 分子量 | 570.8 |
| 溶解度 | DMSO: slightly soluble,Methanol: slightly soluble |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Nelfinavir-d3 is intended for use as an internal standard for the quantification of nelfinavir by GC- or LC-MS. Nelfinavir is an orally bioavailable inhibitor of the HIV-1 protease (Ki =2 nM).1 It demonstrates anticancer activity, selectively preventing the growth of HER2-positive breast cancer cells in vitro by inhibiting Hsp90 (IC50 = 3.1 μM).2 Formulations containing nelfinavir have been used in combination with HIV reverse transcriptase inhibitors for the treatment of HIV infection. |1. Kaldor, S.W., Kalish, V.J., Davies, J.F., II, et al. Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 40(24), 3979-3985 (1997).|2. Shim, J.S., Rao, R., Beebe, K., et al. Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir. J. Natl. Cancer Inst. 104(20), 1576-1590 (2012). |
m.cnreagent.com